434-435 / 2351
Hypoxia-classification
15-gene hypoxia classifier
Effect of hypoxic modification
100
%)
Unclassified patients (n=323)
Placebo
Nimorazole
50%
36%
5
50
75
-regional control (
Events All
Placebo
Nimorazole
HR=0.71 (0.53 to 0.95)
96 156
83 167
P=0.02
0
2
Loco
0 12 24 36 48 60
Time after treatment (months)
More hypoxic tumours
5
100
(%)
Less hypoxic tumours
5
100
(%)
(n=114)
(n=209)
Nimorazole
49%
5
50
7
-regional control
Placebo
Nimorazole
50%
44%
5
50
7
-regional control
Placebo
18%
Events All
Placebo
Nimorazole
HR=0.46 (0.29 to 0.75)
34 43
33 71
P=0.001
0
2
Loco
0 12 24 36 48 60
Time after treatment (months)
Events All
Placebo
Nimorazole
HR=0.85 (0.58 to 1.23)
62 113
50 96
P=0.39
0
2
Loco
0 12 24 36 48 60
Time after treatment (months)
-Toustrup K et al, Radiother Oncol; 102; 122-129, 2012